Skip to main content
HealthReportedLow
2.1

FDA approves Sanofi's venglustat (Infilbray) for neurological Gaucher disease

The FDA approved Sanofi's venglustat (Infilbray), the first oral therapy targeting CNS manifestations of the neurological variant of Gaucher disease. This is a regulatory milestone for a rare-disease indication, but commercial impact is limited by the small patient population. The approval may bolster Sanofi's rare-disease portfolio but is not a macro market signal.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

Infobaeabout 17 hours agoUSCredibility 26%View source

Score Breakdown

Mosaic Score2.1
Model confidence0.9
Significance0.1
Source credibility0.3
Source

Related signals

8 found